Leadsbiolab adheres to the original! Another bispecific antibody has been approved by FDA for clinical trial!

On August 2, 2021, Nanjing Leadsbiolab Biotechnology Co., Ltd. (hereinafter referred to as "Leadsbiolab")has announced that its LBL-024 for PD-L1 / 4-1BB bispecific antibody injection was approved by the U.S. Food and Drug Administration (FDA) for Clinical trial license.

LBL-024 is a bispecific antibody independently researched and developed by leadsbiolab and wholly owned intellectual property rights. LBL-024 is a highly potential anti-tumor bispecific antibody, which consists of high affinity monoclonal antibody against PD-L1 and 4-1BB single chain antibody. LBL-024 can block PD-1 / PD-L1 immunosuppressive pathway and conditionally activate 4-1BB costimulatory receptor, thus playing a dual synergistic role of relieving immunosuppression (releasing the brake) and activating the immune system (stepping on the gas).

Source: Leadsbiolab website